Biohaven Pharmaceutical Holding Company Ltd said on Tuesday two doses of its experimental treatment for acute migraine were effective in reducing headaches in a pivotal study.
The drug, vazegepant, belongs to a new class of treatments for migraine called CGRP inhibitors. more